List of Excipients in Branded Drug EURAX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Journey Medical Corporation	EURAX	crotamiton	69489-311	BENZYL ALCOHOL
Journey Medical Corporation	EURAX	crotamiton	69489-311	CARBOMER HOMOPOLYMER TYPE B
Journey Medical Corporation	EURAX	crotamiton	69489-311	CETYL ALCOHOL
Journey Medical Corporation	EURAX	crotamiton	69489-311	DIAZOLIDINYL UREA

Eurax Excipient Strategy and Commercial Opportunities for Crotamiton Topical Products

Last updated: September 25, 2026

Eurax is a topical crotamiton product, generally supplied as a 10% cream or lotion for scabies and pruritus. Its commercial opportunity is primarily a formulation, regulatory, manufacturing and channel strategy rather than a new-molecule patent play. The strongest development paths are low-irritancy cream, lotion, gel, emulsion and potentially spray formats that improve application, washability, sensory profile and access in markets where branded Eurax is unavailable or weakly protected.

What is Eurax and which active ingredient does it contain?

Eurax contains crotamiton, a topical antipruritic with scabicidal use. Commercial presentations commonly contain crotamiton at 10% w/w, although product status and labeling differ by country.

Attribute	Eurax profile
Brand	Eurax
Active ingredient	Crotamiton
Typical strength	10% w/w
Dosage form	Cream; lotion in some markets
Main uses	Pruritus and scabies
Route	Topical cutaneous
Product category	Small-molecule topical medicine
Biologic status	Not applicable
Biosimilar risk	None
Primary commercial barriers	Regulatory approval, formulation equivalence, trademarks, distribution and consumer recognition

UK product information identifies Eurax Cream as a 10% crotamiton product and lists conventional emulsion excipients, including glyceryl monostearate, polysorbate 60, liquid paraffin, cetostearyl alcohol, propylene glycol and purified water.[1]

Crotamiton is a small, lipophilic active that requires an excipient system capable of maintaining uniform distribution, acceptable skin feel and adequate release from the vehicle. The formulation must also remain physically stable across temperature changes and maintain tolerability on inflamed or excoriated skin.

What excipients are used in Eurax formulations?

The best-documented Eurax formulation is an oil-in-water cream. Exact excipient composition can vary by jurisdiction, manufacturer, product generation and dosage form.

Eurax cream excipient architecture

A conventional Eurax-type cream may use the following functional classes:

Excipient class	Likely function	Commercial significance
Glyceryl monostearate	Emulsifier, consistency agent	Supports cream structure and viscosity
Polysorbate 60	Nonionic surfactant	Stabilizes the oil-in-water emulsion
Cetostearyl alcohol	Co-emulsifier, thickener, emollient	Improves body, spreadability and stability
Liquid paraffin	Emollient and oil phase	Supports occlusivity and skin feel
Propylene glycol	Humectant and cosolvent	Can improve hydration and drug partitioning
Purified water	Continuous phase	Main vehicle component
Preservative system	Microbial control	Required where the formulation and pack create microbial risk
pH adjuster	pH control	Influences stability, preservative performance and irritation

The formulation strategy is conventional, which is commercially useful. Established excipients reduce development risk, support standard topical manufacturing and provide multiple sources for procurement. The main challenge is balancing crotamiton solubilization with emulsion stability and skin tolerability.

Why excipient selection matters for crotamiton

Crotamiton is poorly suited to a simple aqueous solution. A cream, lotion or gel must address:

1. Uniform distribution of the active across the applied dose.
2. Appropriate release from the vehicle into the stratum corneum.
3. Consistent application over large body areas.
4. Acceptable feel after repeated use.
5. Stability under normal storage and transport conditions.
6. Low irritation on damaged or inflamed skin.

Propylene glycol can improve wetting and solvent capacity, but high levels can increase stinging or irritation in some users. Cetostearyl alcohol and paraffin can improve barrier feel but may produce a heavier or greasier product. Polysorbate systems can support emulsification but require compatibility and preservative testing.

The most commercially attractive formulation would preserve crotamiton performance while reducing greasiness, residue, tack and odor.

What formulation strategies could improve Eurax?

Several excipient strategies could support differentiated crotamiton products.

Low-grease oil-in-water cream

A modern oil-in-water cream could reduce the paraffin load, use a lighter ester or triglyceride phase, and retain sufficient emolliency for pruritic skin. This format would target adult consumers who reject heavy ointments and caregivers applying product over large areas.

Development priorities include:

• Faster rub-in.
• Lower residual oil.
• No visible whitening after application.
• Sufficient emulsion stability.
• Low sting on excoriated skin.
• Compatibility with tubes and airless pumps.

This is likely the lowest-risk reformulation route because it remains close to the established Eurax dosage form.

Lotion or fluid emulsion

A lotion can improve coverage for extensive scabies or generalized itching. Lower viscosity supports rapid application across the trunk and limbs, but it creates risks involving runoff, dosing variability and packaging leakage.

A lotion strategy could use:

• A lower internal-phase emulsion.
• Controlled viscosity through polymeric rheology modifiers.
• Humectants at tolerable levels.
• A pump or flip-top package.
• A low-odor oil phase.

The principal regulatory burden is demonstrating that the new formulation delivers an equivalent product performance and remains stable. A lotion may be commercially distinct even where the active strength remains 10%.

Hydrogel or emulgel

An emulgel could combine a low-oil internal phase with a polymeric aqueous network. It may offer a cooler, less greasy feel and improved consumer acceptance.

Potential excipients include carbomers, cellulose derivatives or other topical rheology modifiers. These systems require close control of:

• pH.
• Crotamiton solubilization.
• Polymer compatibility.
• Viscosity over shelf life.
• Drug release.
• Preservative effectiveness.
• Rub-out and drying behavior.

The principal risk is that a highly aqueous system may not maintain adequate crotamiton solubilization or may produce crystallization during storage.

Spray or foam

A spray could improve application convenience for large affected areas and reduce hand contact. It would also create a more difficult regulatory and manufacturing program.

Key issues include:

• Dose per actuation.
• Valve and container compatibility.
• Flammability if volatile propellants or ethanol are used.
• Inhalation and ocular exposure.
• Spray plume and coverage.
• Stability of the active in the device.
• Regulatory classification of the delivery system.

A non-aerosol pump spray is more practical than a pressurized foam for an initial commercial program.

Preservative-free multidose presentation

A preservative-free product could target sensitive-skin users, but the packaging would need to control microbial ingress. Airless pumps, unit-dose sachets or sterile manufacturing approaches could be evaluated.

This strategy may increase cost and packaging complexity. It is more likely to support a premium dermatology position than a mass-market generic position.

What excipient changes create the strongest commercial differentiation?

The most valuable differentiation is likely to come from user experience rather than a new pharmacological claim.

Product concept	Consumer benefit	Development complexity	Commercial potential
Standard equivalent cream	Lower price and broader access	Low	High in generic channels
Low-grease cream	Better cosmetic acceptability	Moderate	High
Fluid lotion	Easier full-body application	Moderate	High for scabies
Emulgel	Cooling, lower residue	Moderate to high	Moderate to high
Pump spray	Contact-free application	High	Moderate
Preservative-free airless cream	Sensitive-skin positioning	High	Niche premium
Pediatric-sensitive cream	Lower irritation profile	Moderate	High if labeling supports use

A low-grease cream and a full-body lotion provide the clearest balance between commercial value and development risk.

What FDA regulatory status and Orange Book issues apply to Eurax?

Crotamiton is a small-molecule topical drug, not a biologic. Biosimilar pathways do not apply. The relevant regulatory route depends on the intended market and the status of the reference product.

In the United States, the Orange Book identifies approved drug products and relevant patent and exclusivity information. A developer must verify whether a current crotamiton reference product is listed, whether it is actively marketed, and whether an abbreviated new drug application pathway is available.[2]

U.S. regulatory considerations

A prospective U.S. product may face one of several pathways:

• ANDA, if an eligible reference product and pharmaceutical equivalence framework exist.
• NDA under section 505(b)(2), if the formulation, dosage form or reference basis differs materially.
• OTC monograph or monograph-like route only if the product fits applicable current FDA requirements.

A reformulated cream, lotion, gel or spray should not be assumed to qualify automatically as an ANDA product. Differences in vehicle, dosage form, inactive ingredients, delivery device or labeling can move the product toward a 505(b)(2) strategy.

FDA inactive-ingredient precedents can reduce risk but do not replace formulation-specific safety and performance work.[3]

European and other market considerations

Eurax has historically had a stronger presence in some non-U.S. markets, including the United Kingdom. In those markets, the key questions are product authorization status, national reference-product requirements, variation rules and trademark ownership.

A reformulation may require:

• Pharmaceutical development and comparative quality data.
• Microbiological quality and preservative-effectiveness data.
• In vitro release testing.
• Skin permeation or local availability studies where required.
• Irritation and sensitization assessment.
• Stability data in the final container closure system.
• Updated labeling for excipients with known effects.

When does Eurax lose exclusivity and what patents protect it?

Eurax is an established topical brand rather than a recently launched innovative drug. The commercial assessment should therefore distinguish between active-ingredient exclusivity, formulation patents, trademarks and regulatory exclusivity.

Protection category	Eurax relevance
New chemical entity exclusivity	Historical and no longer the main barrier
Active-ingredient patent	Not the principal commercial barrier for an established crotamiton product
Formulation patent	Must be assessed by jurisdiction and product owner
Method-of-use patent	Potentially relevant but generally narrower for an established antipruritic
Trademark	Potentially important for the Eurax name and trade dress
Regulatory exclusivity	Depends on country and current authorization
Manufacturing know-how	May remain relevant even without blocking patents

No biologic exclusivity or biosimilar patent dance applies. A generic or reformulated entrant must focus on product approval, trademark avoidance, formulation know-how and supply reliability.

A current freedom-to-operate review should cover published patent families for:

• Crotamiton creams and lotions.
• Enhanced skin delivery systems.
• Combination products containing crotamiton.
• Scabies treatment regimens.
• Preservative-free or device-based presentations.
• Manufacturing processes and packaging systems.

Patent risk is likely to be lower for a conventional 10% cream using established excipients than for a differentiated spray, emulgel or combination product.

Are Paragraph IV challenges, litigation or settlement agreements material?

Paragraph IV risk is relevant only if a U.S. reference product and listed patent framework support an ANDA challenge. It is not automatically applicable to every crotamiton product.

Publicly visible commercial risk should be divided into four categories:

1. Orange Book-listed patents, if any.
2. Unlisted formulation or process patents.
3. Trademark and trade-dress disputes.
4. Product liability or regulatory enforcement.

For a conventional generic cream, litigation exposure is likely to center on formulation patents, labeling and trademark issues rather than a live composition-of-matter patent. A 505(b)(2) product may face different patent certification and litigation issues from an ANDA product.

No confirmed current settlement agreement should be assumed without a product-specific review of FDA litigation records, federal court dockets and patent assignment databases. FDA’s Orange Book and Drugs@FDA records are the primary starting points for U.S. status verification.[2,4]

Which companies could challenge or compete with Eurax?

Competition is likely to come from several groups rather than one direct branded rival.

Generic pharmaceutical manufacturers

Generic manufacturers can compete with crotamiton cream or lotion on price, pharmacy availability and private-label supply. Their advantages are lower marketing costs and established topical manufacturing networks.

Dermatology and consumer-health companies

These companies may compete through:

• Itch-relief creams.
• Scabies treatments containing alternative actives.
• Emollients and barrier-repair products.
• Antihistamine or antipruritic products.
• Prescription topical steroids for selected diagnoses.

These products do not necessarily provide direct pharmaceutical equivalence, but they compete for the same consumer and clinician decision.

Contract manufacturers and private-label suppliers

A contract manufacturer could supply a retailer-branded crotamiton product with a lower-cost cream or lotion. This creates a route to market without building a consumer brand, particularly in pharmacy, online and public-health procurement channels.

What generic launch scenarios exist for Eurax?

Scenario 1: Price-led generic cream

A standard 10% cream closely aligned with the established product would have the lowest development risk. The opportunity depends on reference-product status, market size, reimbursement and pharmacy substitution.

Scenario 2: Differentiated full-body lotion

A lotion could command better channel access in scabies treatment because application over large areas is easier. Commercial claims must remain within the approved labeling.

Scenario 3: Premium low-irritancy product

A low-grease, low-odor product could target sensitive skin and repeat users. The premium depends on demonstrated cosmetic and tolerability advantages, not merely on a longer excipient list.

Scenario 4: Institutional supply

Scabies outbreaks in care homes, shelters, hospitals and correctional settings create an institutional opportunity. Buyers prioritize:

• Reliable supply.
• Simple application instructions.
• Large pack sizes.
• Low unit cost.
• Low risk of leakage and contamination.
• Stable shelf life.

A lotion or pump presentation may be more operationally useful than a traditional tube in these settings.

How strong is the patent estate for Eurax?

The apparent patent position is weaker than the commercial brand position. Crotamiton is an established active ingredient, and a conventional cream using well-known excipients is unlikely to obtain broad, durable exclusivity solely from routine formulation choices.

A stronger patent position would require a technically differentiated claim set, such as:

• A defined crotamiton particle-size distribution.
• A specific solvent or emulsion architecture.
• Improved local delivery with reduced systemic exposure.
• A stable preservative-free composition.
• A metered-dose device with reproducible delivery.
• A validated combination treatment.
• A manufacturing process that produces a demonstrated performance advantage.

Patent strength would be highest when the claims are supported by comparative data against the incumbent product. A formulation patent based only on substituting one common emulsifier for another would face greater validity and design-around risk.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to involve product rights, manufacturing capacity and regional distribution than a novel active-ingredient license.

Potential deal structures include:

Deal type	Strategic purpose
Regional brand license	Enter markets where Eurax recognition remains strong
Private-label supply agreement	Secure pharmacy or retailer distribution
Formulation license	Transfer a low-grease cream, lotion or spray platform
Contract development and manufacturing	Reduce capital expenditure
Institutional procurement agreement	Obtain recurring public-health volume
Trademark coexistence or acquisition	Avoid brand-entry disputes

A formulation owner could license a finished product to regional distributors while retaining manufacturing control. A generic manufacturer could instead pursue a supply agreement with a national pharmacy chain.

Key Takeaways

• Eurax is a 10% crotamiton topical product, commonly supplied as a cream and, in some markets, a lotion.
• The most practical excipient opportunity is a low-grease oil-in-water cream with improved spreadability and reduced residue.
• A full-body lotion is commercially attractive for scabies treatment but requires tighter control of runoff, dosing and packaging.
• Emulgels, pump sprays and preservative-free systems offer differentiation but carry higher regulatory and technical risk.
• Biosimilar competition is irrelevant because crotamiton is a small molecule.
• U.S. market entry depends on current reference-product status and whether an ANDA, 505(b)(2) NDA or another pathway is available.
• The principal legal risks are jurisdiction-specific formulation patents, trademarks, trade dress and regulatory exclusivity.
• The strongest commercial strategy is likely a conventional-equivalent product for price channels paired with a differentiated low-residue formulation for pharmacy and dermatology channels.
• Institutional and private-label supply may offer more predictable volume than a heavily branded consumer launch.

FAQs About Eurax Excipient and Commercial Strategy

Can propylene glycol be removed from a Eurax-type crotamiton cream?

Yes. Removal is technically possible, but the developer must reassess crotamiton solubilization, emulsion stability, skin feel, drug release, preservative performance and local tolerability.

Is a crotamiton lotion easier to develop than a crotamiton cream?

No. A lotion may be simpler to apply, but it creates additional risks involving phase separation, runoff, dose variability, container leakage and full-body coverage.

Can a generic manufacturer use the Eurax name?

No. The Eurax name and associated branding may be protected by trademark rights. A generic entrant would normally require its own brand or a compliant nonproprietary presentation.

Does a new crotamiton excipient combination automatically receive patent protection?

No. Patentability depends on novelty, inventive step, claim scope and supporting technical evidence. Routine substitution of known topical excipients is unlikely to provide strong exclusivity by itself.

Is a crotamiton spray a meaningful commercial opportunity?

Potentially. A pump spray could improve contact-free application and full-body coverage, but device performance, dose uniformity, inhalation exposure, packaging compatibility and regulatory classification materially increase development requirements.

References

1. Electronic Medicines Compendium. (n.d.). Eurax cream: Summary of product characteristics.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2019). Inactive ingredient database.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.